Navigation Links
Arena Pharmaceuticals Announces Initiation by Merck of Phase 2 Clinical Trial of Niacin Receptor Agonist
Date:2/18/2009

SAN DIEGO, Feb. 18 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today the initiation of a Phase 2 clinical trial of an orally administered niacin receptor agonist drug candidate being developed by Merck & Co., Inc., under its collaboration with Arena to treat atherosclerosis. Agonists of the niacin receptor have the potential to regulate plasma lipid profiles, including HDL, or the "good" cholesterol, similar to the therapeutic action of niacin. The initiation of this trial does not trigger a milestone payment.

The Phase 2 clinical trial is a randomized, double-blind, placebo-controlled study evaluating the safety, tolerability, as well as potential efficacy, of the niacin receptor agonist in patients with dyslipidemia.

"We are pleased with Merck's decision to advance this niacin receptor agonist into Phase 2," said Jack Lief, Arena's President and Chief Executive Officer. "We look forward to the Phase 2 results and to the possible continued advancement of this program."

About Arena Pharmaceuticals

Arena is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs in four major therapeutic areas: cardiovascular, central nervous system, inflammatory and metabolic diseases. Arena's most advanced drug candidate, lorcaserin, is being investigated in a Phase 3 clinical trial program for the treatment of obesity. Arena's broad pipeline of novel compounds target G protein-coupled receptors, an important class of validated drug targets, and includes compounds being evaluated independently and with partners, including Merck & Co., Inc., and Ortho-McNeil-Janssen Pharmaceuticals, Inc.

Arena Pharmaceuticals(R) and Arena(R) are registered service marks of the company. "APD" is an abbreviation for
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
2. Arena Pharmaceuticals Announces Public Offering of Common Stock
3. Arena Pharmaceuticals to Present at the BIOCOM Investor Conference
4. Arena Pharmaceuticals Announces Pricing of Public Offering of Common Stock
5. Arena Pharmaceuticals to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
6. Arena Pharmaceuticals Lorcaserin for Obesity Passes Major Safety Milestone
7. Arena Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Unplugged Conference
8. Arena Pharmaceuticals to Report First Quarter 2008 Financial Results and to Host Conference Call and Webcast on Wednesday, May 7, 2008
9. Field Poll: California Nurses Association Most Favorably Viewed Group in Healthcare Arena
10. Childrens Miracle Network and Arena Football League Partner for First Nationwide Celebration Event
11. Arena Pharmaceuticals Announces Third Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... ... 2015 , ... Since 1946, the doctors and staff at Clifton Dental Associates ... patient arrives at the office, the staff will make them feel welcome and comfortable. ... to create a complete dental treatment plan that is unique to each smile! ...
(Date:8/31/2015)... ... August 31, 2015 , ... How can healthcare meet ... down costs? , In a commentary for The American Journal of Managed ... of “clinical efficacy,” which would bind parties together in agreements to intervene at ...
(Date:8/31/2015)... (PRWEB) , ... August 31, 2015 , ... Three Bakers ... visitors and retailers with even more relevant and easy-to-find information on their offering of ... “Our website has always been an important way for us to share information about ...
(Date:8/31/2015)... ... 2015 , ... Physicians’ Education Resource®, LLC (PER®) , ... Cancer Therapy for Tomorrow® meeting, is seeking abstract submissions for its 33rd ... The annual legacy meeting uses a variety of formats to educate all disciplines ...
(Date:8/31/2015)... ... August 31, 2015 , ... With baseball season in full swing, many ... will dominate the sports world. Fans desire nothing more than to see their favorite ... For children, especially those who are too young to really understand what all the ...
Breaking Medicine News(10 mins):Health News:NJ Top Dentists Presents, Clifton Dental Associates! 2Health News:How “Clinical Efficacy” Can Rein in Healthcare Costs 2Health News:How “Clinical Efficacy” Can Rein in Healthcare Costs 3Health News:Three Bakers Gluten Free Bakery Announces Launch of New Website 2Health News:Physicians’ Education Resource® Seeks Abstracts for the Upcoming Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® 2Health News:Physicians’ Education Resource® Seeks Abstracts for the Upcoming Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® 3Health News:Physicians’ Education Resource® Seeks Abstracts for the Upcoming Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® 4Health News:New Children's Baseball Series Offers Young Fans a Way to Celebrate the World Series 2
... -- Researchers and clinicians from the Indiana University School ... distinction between lab and clinic as they debut the ... care model they developed and extensively tested over the ... care is on two groups -- patients with cognitive ...
... International Journal of Emergency Medicine, a new quarterly publication ... research developments from around the world in emergency medicine. ... be available free of charge exclusively on Springers online ... issue will be published online in March 2008. , ...
... CHICAGO, Feb. 19 Viola Startzman, M.D. of,Wooster, Ohio ... M.D. Award for,Excellence in Volunteerism. Presented by the American ... domestic physicians for,commitment to volunteer medical care to those ... Foundation presents the award in association with the,Pfizer Medical ...
... M.D.,MDiv, of Memphis, Tenn., is a recipient of the ... Medical Association (AMA) Foundation, the,award is given to domestic ... Foundation presents the award in association with the,Pfizer Medical ... Monday, March 31st, at the 2008,Excellence in Medicine Awards ...
... Murli Manohar, M.D., Ph.D.,FACP, of Canton, Ohio, is a ... by the American Medical Association (AMA) Foundation, the,award is ... U.S. The AMA Foundation presents the award in association ... be presented on Monday, March 31st, at the 2008,Excellence ...
... Choices ( http://www.nhs.uk ),the digital ,front door, to ... help people assess their drinking behaviour and improve ... Based on NHS accredited information, the drinking assessment ... seconds whether they are drinking too much, and ...
Cached Medicine News:Health News:Merging discovery with therapy: Second generation memory care debuts 2Health News:Merging discovery with therapy: Second generation memory care debuts 3Health News:Springer to launch new journal in emergency medicine 2Health News:AMA Foundation Honors Wooster, Ohio Physician for Volunteerism 2Health News:AMA Foundation Honors Memphis, Tennessee Physician for Increasing Access to Health Care in the U.S. 2Health News:AMA Foundation Honors Canton, Ohio Physician for Increasing Access to Health Care in the U.S. 2
(Date:8/31/2015)... HARRISBURG, Pa. , Aug. 31, 2015 ... been reversed statewide since Pennsylvania ... the life-saving drug kits, naloxone. Heroin and ... in Pennsylvania , killing more individuals ... 2013, approximately 2,400 Pennsylvanians died from a drug overdose. ...
(Date:8/31/2015)... DIEGO , Aug. 31, 2015 Regen ... today development of a novel means of delivering ... acid, RGBP-248, to liver tumors utilizing a clinically ... development overcomes previous hurdles with gene silencing therapeutics ... be delivered throughout the whole body.  By utilizing ...
(Date:8/31/2015)... PRINCETON, N.J. , Aug. 31, 2015  /PRNewswire/ ... Company), a late-stage biopharmaceutical company developing products that ... inflammation, oncology and biodefense, announced today it has ... by the Data Review Committee (DRC) earlier this ... SGX942.  SGX942 is a first-in-class innate defense regulator ...
Breaking Medicine Technology:Departments of Drug & Alcohol Programs and Health Announce Report 289 Pennsylvanian Lives Saved by Naloxone 2Departments of Drug & Alcohol Programs and Health Announce Report 289 Pennsylvanian Lives Saved by Naloxone 3Regen BioPharma, Inc. Develops BORIS Gene Silencing Based Treatment for Unresectable Liver Cancer 2Regen BioPharma, Inc. Develops BORIS Gene Silencing Based Treatment for Unresectable Liver Cancer 3Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 2Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 3Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 4Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 5Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 6
... , , , SAN DIEGO, ... dedicated to developing life-saving medicines specifically designed to enhance ... through targeted oxygen delivery, today announced the initiation of ... efficacy of MP4OX treatment plus standard of care in ...
... Dec. 9 The U.S. Food and Drug Administration ... workshop series--an opportunity for biotechnology companies, pharmaceutical firms, academics ... applications for orphan status designation, under the guidance of ... The first workshop is planned for Feb. 25-26, 2010, ...
Cached Medicine Technology:Sangart, Inc. Initiates Phase IIa Study of Oxygen Therapeutic Agent MP4OX in Severe Trauma Patients With Hemorrhagic Shock 2Sangart, Inc. Initiates Phase IIa Study of Oxygen Therapeutic Agent MP4OX in Severe Trauma Patients With Hemorrhagic Shock 3FDA Launches Orphan Drug Workshop at KGI 2
The COBE 2991 Cell Processor provides reliable, automated cell processing, with the control you need to get reproducible results in your lab. This versatile machine offers users reliability and multi...
The Wallac Multipette is used with 5 mL or 2.5 mL Combitips....
The Eppendorf Maxipettor is a continuously adjustable pipette for precise pipetting of volumes up to 10 ml (in 10 l increments). Even liquids with a high vapor pressure or viscosity can be pipetted w...
... lightweight and balanced for smooth, one-handed control. ... comfort, reducing fatigue in even the longest ... physician to easily steer the catheter through ... one finger. Reflexion's auto-lock technology keeps the ...
Medicine Products: